Hyperthermia-based Prophylatic therapy against SARS-COV-2/COVID-19: Hyperthermia (40C to 43C) inhibits SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 15/April/2020, 12.27 am

A potential vaccine against SARS-COV-2: Repurposing the IB-ND Virus-like particles (VLPs) vaccine  into a Prophylactic IB-ND VLPs-COVID-19 vaccine: A novel chimeric infectious bronchitis-Newcastle disease (IB-ND) virus-like particles (VLPs) inhibit SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 12/April/2020, 11.01 pm
April 12, 2020
Hypertonic saline-based Prophylatic therapy for SARS-COV-2/COVID-19: Hypertonic saline (Nacl) inhibits SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, Respiratory Syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 10/May/2020, 12.50am
May 9, 2020
Show all

Introduction: What they say:

A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.” This study was published, in the 24 December 2009 issue of the journal “Cell” (the number 1 research journal in General Biology with an impact factor of 33),  by the 2015 Laskar award winner Prof. Stephen Elledge, Brass and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Hyperthermia-based Prophylatic therapy against SARS-COV-2/COVID-19: Hyperthermia (40C to 43C) inhibits SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 15/April/2020, 12.27 am


What is known?

Prof. Stephen Elledge research team has showed that interferon-inducible transmembrane proteins IFITM1, 2, and 3 inhibit  influenza A H1N1 virus, West Nile virus, and dengue virus replication, suggesting that increasing the expression of IFITM3 may confer resistance against these viruses. Other studies suggest that IFITM3 may also protect against Ebola virus, hepatitis C virus, yellow fever virus and SARS coronavirus etc.


From research findings to therapeutic opportunity: 

This study suggests, for the first time, that Hyperthermia (40C to 43C for about 20 minutes)-based therapy, with detailed mechanistic insights, for COVID-19 and other infectious diseases. Hyperthermia (40C to 43C), by increasing the expression of its target genes, it could increase the expression of interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides. Thereby, it could: (1) inhibit the replication of  SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses; (2) confer resistance against  infection caused by SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Foot and Mouth disease, ADV, Influenza H1NI1,  respiratory syncytical,  Sindbis, and SFV viruses; and (3) promote innate immunity (Figures 1-5) Thus, Hyperthermia (40C to 43C), either alone or in combination with other drugs/compounds, can be used to prevent/treat/protect against infections caused by SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Foot and Mouth disease, ADV (Adenovirus), Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses.

Figure 1. Mechanistic insight into how Hyperthermia (40C to 43C)  prevents/protects against SARS-COV-2. Hyperthermia inhibits SARS-COV-2 &  SARS-COV-1 through induction of its target genes, such as antiviral Proteins IFITM3, Interferon-stimulated gene 15, Mx2, and others.

 

Figure 2 Mechanistic insight into how Hyperthermia (40C to 43C)  functions as a broad spectrum anti-infective agent. Hyperthermia inhibits SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial , Sindbis, Foot and Mouth disease virus, ADV, and SFV viruses production through induction of its target genes, such as antiviral Proteins IFITM3, Interferon-stimulated gene 15, Mx2 and others.

 

This image has an empty alt attribute; its file name is Hyperthermia-aids-in-attenuation-of-SARS-coronavirus-2-SARSCOV2-4-770x578.jpg

Figure 3.  Hyperthermia (40C to 43C)  can prevent/treat/protect against SARS-COV-2.

 

Figure 4.  Hyperthermia (40C to 43C)  can function as a broad-spectrum anti-infective agent.

 

Figure 5.  Hyperthermia-based preventive therapy against SARS-COV-2. GBMD (genomediscovery.org) is looking for Scientists/Professor/Medical faculties who would be interested in collaborating with us.


Details of the research findings: 

Idea formulated by Dr L Boominathan PhD

Undisclosed information: How hyperthermia (40C to 43C)  increases the expression of antiviral Protein, such as IFITM3, Interferon-stimulated gene 15, Mx2, and others

Type: Research cooperation

For more details on research cooperation, you may reach us at drboomi@genomediscovery.org or admin@genomediscovery.org


References: 

CitationBoominathan L, Hyperthermia-based Prophylatic therapy against SARS-COV-2/COVID-19: Hyperthermia (40C to 43C) inhibits SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 15/April/2020, 12.27 am

Courtesy: When you cite drop us a line at info@genomediscovery.org,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Comments are closed.